Safety data from 9 phase 3 UPA trials (RA, PsA & AS). In 11,271 pt-yrs exposure, no increased signal for cancer (excluding NMSC) cf. ADA/MTX. NMSC was higher however. What data (if any) would reassure people in this space? @RheumNow ABST0292 #ACR22 https://t.co/tS5r66loqP